IL1B and metabolic dysfunction-associated steatohepatitis: reported that, in addition to decreasing liver lipid content, adropin treatment reduced the expression of pro-inflammatory cytokines, including IL-1β, IL-6, and TNF-α, in MCD diet-induced NASH mice (10), indicating its anti-inflammatory effects in NASH.